Literature DB >> 10954277

Reversible tacrolimus-induced neurotoxicity isolated to the brain stem.

P J Oliverio1, L Restrepo, S A Mitchell, C S Tornatore, S R Frankel.   

Abstract

Diplopia, nystagmus, visual hallucinations, and internuclear ophthalmoplegia developed in a 30-year-old woman 84 days after she received a matched, unrelated bone marrow transplant for chronic myeloid leukemia. A regimen of tacrolimus had been administered since the transplantation was performed. MR imaging revealed bilaterally symmetric regions of signal abnormality with abnormal contrast enhancement in the brain stem. No supratentorial abnormality was present. Tacrolimus therapy was discontinued, and the symptoms resolved. MR imaging that was performed 10 days after tacrolimus was discontinued showed resolution of the abnormalities.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10954277      PMCID： PMC8174919     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  13 in total

1.  Expressive dysphasia possibly related to FK506 in two liver transplant recipients.

Authors:  J Reyes; T Gayowski; J Fung; S Todo; M Alessiani; T E Starzl
Journal:  Transplantation       Date:  1990-12       Impact factor: 4.939

2.  Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation.

Authors:  L A Shutter; J P Green; N J Newman; M A Hooks; R D Gordon
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

3.  Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction.

Authors:  Y Ito; H Niwa; T Iida; M Nagamatsu; T Yasuda; T Yanagi; G Sobue
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

4.  Transient neurotoxicity associated with FK506: MR findings.

Authors:  N Tomura; R Kurosawa; K Kato; S Takahashi; J Watarai; O Takeda; A Watanabe; G Takada
Journal:  J Comput Assist Tomogr       Date:  1998 May-Jun       Impact factor: 1.826

5.  The reversible posterior cerebral edema syndrome.

Authors:  W P Dillon; H Rowley
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

6.  Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506)

Authors:  S L Small; M B Fukui; G T Bramblett; B H Eidelman
Journal:  Ann Neurol       Date:  1996-10       Impact factor: 10.422

7.  Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.

Authors:  R E Steg; A Kessinger; Z K Wszolek
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

8.  Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

Authors:  Y Ito; Y Arahata; Y Goto; M Hirayama; M Nagamutsu; T Yasuda; T Yanagi; G Sobue
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

9.  MR imaging of reversible cyclosporin A-induced neurotoxicity.

Authors:  C L Truwit; C P Denaro; J R Lake; T DeMarco
Journal:  AJNR Am J Neuroradiol       Date:  1991 Jul-Aug       Impact factor: 3.825

10.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245
View more
  12 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

2.  Pearls & Oy-sters: Tacrolimus neurotoxicity presenting as an isolated brainstem lesion.

Authors:  Altaf Saadi; Jeremy D Schmahmann
Journal:  Neurology       Date:  2016-03-15       Impact factor: 9.910

3.  Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis.

Authors:  Hafez Mohammad Ammar Abdullah; Waqas Ullah; Ejaz Ahmad; Faiz Anwer
Journal:  BMJ Case Rep       Date:  2016-08-17

4.  Clinicoradiological factors influencing the reversibility of posterior reversible encephalopathy syndrome: a multicenter study.

Authors:  Ajaya R Pande; Kumiko Ando; Reiichi Ishikura; Yuki Nagami; Yoshihiro Takada; Akihiko Wada; Yoshiyuki Watanabe; Yukio Miki; Akira Uchino; Norio Nakao
Journal:  Radiat Med       Date:  2006-12-25

5.  [Postoperative occurrence of reversible posterior encephalopathy in a patient with Crohn's disease].

Authors:  S G Zipper; M Tischendorf; K Westphal
Journal:  Anaesthesist       Date:  2006-10       Impact factor: 1.041

6.  Analysis of magnetic resonance imaging findings of children with neurologic complications after liver transplantation.

Authors:  Mehmet Öztürk; İsmail Akdulum; Nurullah Dağ; Ahmet Sığırcı; Serdal Güngör; Sezai Yılmaz
Journal:  Radiol Med       Date:  2017-04-03       Impact factor: 3.469

7.  A brainstem variant of reversible posterior leukoencephalopathy syndrome.

Authors:  H Kitaguchi; H Tomimoto; Y Miki; A Yamamoto; K Terada; H Satoi; M Kanda; H Fukuyama
Journal:  Neuroradiology       Date:  2005-06-10       Impact factor: 2.804

8.  Reversible encephalopathy syndrome: report of 12 cases with follow-up.

Authors:  S Greco Crasto; L Rizzo; P Sardo; O Davini; R De Lucchi
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

9.  Posterior reversible encephalopathy syndrome: the importance of early diagnosis.

Authors:  Rute Teotónio; Dina Marmoto; Cristina Januário; Conceição Bento
Journal:  BMJ Case Rep       Date:  2012-09-17

10.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.